EcoDrugPlus

C-C Chemokine Receptor Type 1

Ensembl ID : ENSMOCG00000001246
Gene Symbol: LOC101980687
3 Cross references
291 Possible Orthologues:

C-C Chemokine Receptor Type 5

Ensembl ID : ENSMOCG00000016137
Gene Symbol: LOC101982275
3 Cross references
298 Possible Orthologues:

C-C Motif Chemokine Receptor 2

Ensembl ID : ENSMOCG00000011120
Gene Symbol: CCR2
3 Cross references
286 Possible Orthologues:

C-C Motif Chemokine Receptor 4

Ensembl ID : ENSMOCG00000016957
Gene Symbol: CCR4
3 Cross references
254 Possible Orthologues:

C-C Motif Chemokine Receptor 9

Ensembl ID : ENSMOCG00000022024
Gene Symbol: CCR9
3 Cross references
262 Possible Orthologues:

C-X-C Chemokine Receptor Type 1

Ensembl ID : ENSMOCG00000006635
Gene Symbol: LOC101983285
3 Cross references
158 Possible Orthologues:

C-X-C Chemokine Receptor Type 2

Ensembl ID : ENSMOCG00000005561
Gene Symbol: LOC102000826
3 Cross references
237 Possible Orthologues:

C-Type Lectin Domain Family 4 Member A-Like

Ensembl ID : ENSMOCG00000014857
Gene Symbol: LOC101980661
3 Cross references
708 Possible Orthologues:

C-Type Lectin Domain Family 4 Member A-Like

Ensembl ID : ENSMOCG00000020096
Gene Symbol: LOC101981233
2 Cross references
722 Possible Orthologues:

Cf Transmembrane Conductance Regulator

Ensembl ID : ENSMOCG00000007371
Gene Symbol: CFTR
3 Cross references
216 Possible Orthologues:

Dna Methyltransferase 1

Ensembl ID : ENSMOCG00000013903
Gene Symbol: DNMT1
3 Cross references
206 Possible Orthologues:

Dna Topoisomerase I

Ensembl ID : ENSMOCG00000006200
Gene Symbol: TOP1
3 Cross references
270 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).